
Roche’s Tecentriq combo outclasses Nexavar in unresectable hepatocellular carcinoma
pharmafile | November 25, 2019 | News story | Research and Development, Sales and Marketing |ย ย Cancer, Roche, immunotherapy, pharma, tecentriqย
Roche has revealed new Phase 3 data for its immunotherapy drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the treatment of unresectable hepatocellular carcinoma (HCC) in patients who have not received prior systemic therapy.
The company announced the findings at the European Society for Medical Oncology (ESMO) Asia Congress 2019 on Saturday.
The data illustrated that Rocheโs combo boosted overall survival rates by 42% and progression-free survival rates by 41% compared to Bayerโs Nexavar (sorafenib) โ improvements which Roche called โsignificant and clinically meaningfulโ.
โFor the first time in a decade, we are seeing a treatment that has improved overall survival for people with unresectable hepatocellular carcinoma compared with the current standard of care,โ said Dr Levi Garraway, Chief Medical Officer and Head of Global Product Development. โTecentriq in combination with Avastin could transform the treatment of this aggressive disease, and we are working closely with global health authorities in the hope of bringing this treatment option to patients as soon as possible.โ
Tecentriq is currently undergoing Phase 3 trials in a range of indications with further studies planning, including in lung, skin, breast, head and neck, gastrointestinal, gynaecological and genitourinary cancers.
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

CuraCell granted approval for trial of new therapy for metastatic cancers
Swedish immunotherapy company, CuraCell, has received approval from the Paul-Ehrlich-Institut in Germany to begin a …

Central nervous system cancer metastases โ the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds






